Which statement best describes ELVN-001 and the Phase I ENABLE results presented at SOHO in heavily pretreated chronic-phase CML?
ELVN-001 is an allosteric (STAMP) inhibitor like asciminib, and major molecular response (MMR) rates were about 30%, with little activity after prior asciminib.
ELVN-001 is a highly selective ATP-competitive ABL1 inhibitor with minimal off-target effects; about 60% or more of patients achieved MMR by six months, mainly at the 80 mg once-daily optimal biologic dose, including patients previously exposed to asciminib.
ELVN-001 is a highly selective ATP-competitive ABL1 inhibitor, but it was tested only in TKI-naïve patients, with a discontinuation rate due to adverse events of about 25%.